| |
QFT-IT +
|
QFT-IT -
|
Total
|
κ
|
|---|
|
All participants
| | | |
0.48
|
|
TST +
|
26 (14.7)
|
11 (6.2)
|
37
| |
|
TST -
|
23 (13.0)
|
117 (66.1)
|
140
| |
|
Total
|
49
|
128
|
177
| |
|
Immunocompetent group
| | | |
0.57
|
|
TST +
|
17 (20.0)
|
8 (9.4)
|
25
| |
|
TST -
|
7 (8.2)
|
53 (62.4)
|
60
| |
|
Total
|
24
|
61
|
85
| |
|
Immunocompromised group
| | | |
0.38
|
|
TST+
|
9 (9.8)
|
3 (3.3)
|
12
| |
|
TST -
|
16 (17.4)
|
64 (69.6)
|
80
| |
|
Total
|
25
|
67
|
92
| |
|
Immunocompromised group*
| | | |
0.40
|
|
TST+*
|
14 (15.2)
|
11 (12.0)
|
25
| |
|
TST -*
|
11 (12.0)
|
56 (60.9)
|
67
| |
|
Total
|
25
|
67
|
92
| |
- Data are presented as numbers (percentages) unless otherwise indicated.
- QFT-IT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
-
*Agreement between the two tests with a 5-mm induration cut off for the TST in the immunocompromised group.
